Recombinant GRP94 Monoclonal Antibody (AN301542L)
-
-
-
- +2
For research use only.
| Verified Samples |
Verified Samples in WB: HeLa, MCF-7, MOLT-4, Rat brian, Mouse brain Verified Samples in IF: MCF7 Verified Samples in IHC: Human colon cancer, Human lung squamous carcinoma Verified Samples in IP: HeLa cells extracts |
| Dilution | WB 1:500-1:2000, IHC 1:200-1:1000, IF 1:50, IP 1:25-1:100 |
| Isotype | IgG, κ |
| Host | Rabbit |
| Reactivity | Human, Rat, Mouse |
| Applications | WB, IF, IHC, IP |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Recombinant human GRP94 fragment |
| Abbre | GRP94 |
| Synonyms | HEL, TRA, GRP, HSP90B, HSP90B1, ECGP, GP96, GRP94, HEL-S-125m, HEL35, TRA1, endoplasmin, ECGP, endoplasmin, GP96, GRP94, HEL35, HEL-S-125m, TRA1, 90 kDa, 94 kDa glucose regulated protein, 94 kDa glucose-regulated protein, beta, Endothelial cell (HBMEC) glycoprotein, ENPL, ERp99, Glucose regulated protein 94kDa, gp96 homolog, GRP 94, GRP-94, Heat shock protein, Heat shock protein 90 kDa beta member 1, heat shock protein 90kDa beta (Grp94), Heat shock protein 90kDa beta member 1, member 1, Stress inducible tumor rejection antigen GP96, tumor rejection antigen (gp96) 1, Tumor rejection antigen 1, Tumor rejection antigen gp96, Tumor rejection antigen-1 (gp96) |
| Swissprot | |
| Calculated MW | 94 kDa |
| Observed MW |
100 kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Endoplasmic reticulum |
| Concentration | 1 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A purified |
| Research Areas | Tags & Cell Markers, Signal Transduction, Cancer, Metabolism |
| Clone No. | A241 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | Molecular chaperone that functions in the processing and transport of secreted proteins. When associated with CNPY3, required for proper folding of Toll-like receptors. Functions in endoplasmic reticulum associated degradation (ERAD). Has ATPase activity. May participate in the unfolding of cytosolic leaderless cargos (lacking the secretion signal sequence) such as the interleukin 1/IL-1 to facilitate their translocation into the ERGIC (endoplasmic reticulum-Golgi intermediate compartment) and secretion; the translocation process is mediated by the cargo receptor TMED10. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
